<?xml version="1.0" encoding="UTF-8"?>
<p id="p0095">Notably, one study reported lower lymphocyte levels and platelet counts in COVID-19 patients presenting with CNS symptoms compared to those without CNS involvement 
 <xref rid="b0045" ref-type="bibr">[9]</xref>, 
 <xref rid="b0050" ref-type="bibr">[10]</xref>. Patients with severe disease were also found to possess higher levels of D-dimer, a marker of a hypercoagulable state and of endogenous fibrinolysis, which could possibly explain why acute cerebrovascular disease more commonly develops in such patients 
 <xref rid="b0045" ref-type="bibr">[9]</xref>, 
 <xref rid="b0050" ref-type="bibr">[10]</xref>. It has therefore been suggested that anti-inflammatory pathways could potentially be targeted early on, aiming to reduce the risk of acute cerebrovascular disease 
 <xref rid="b0050" ref-type="bibr">[10]</xref>.
</p>
